Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Novocure - You Need To See This

A Cyberattack on a Cancer Device Maker Exposed Patient Records as Health Care Breaches Pile Up

Novocure says a mid-August cyberattack exposed records for more than 1,400 U.S. patients, the latest in a run of health care breaches.

Top 3 Health Care Stocks That May Explode In July

Top 3 Health Care Stocks That May Explode In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Navigating 5 Analyst Ratings For NovoCure

Navigating 5 Analyst Ratings For NovoCure

5 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2022

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022

Looking Into NovoCure's Return On Capital Employed

Looking Into NovoCure's Return On Capital Employed

According to data from Benzinga Pro, during Q1, NovoCure's (NASDAQ:NVCR) reported sales totaled $137.55 million. Despite a 82.44% increase in earnings, the company posted a loss of $4.65 million.

NovoCure: Q1 Earnings Insights

NovoCure: Q1 Earnings Insights

NovoCure (NASDAQ:NVCR) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Novocure's TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control

Novocure's TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control

Novocure Ltd (NASDAQ: NVCR)

Where NovoCure Stands With Analysts

Where NovoCure Stands With Analysts

NovoCure (NASDAQ:NVCR) has observed the following analyst ratings within the last quarter:

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Berkshire Hathaway

Micron Technology

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Social Security

Places

415,728 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play